Abstract
Objective Cytochrome b5 reductase (CYB5R) and cytochrome P450 reductase (CYPOR) play an important role in cell metabolism; however, their role in thyroid hormonogenesis and carcinogenesis has not been studied. The activity of CYB5R correlates with metastasizing in breast cancer, but there are no similar studies for CYB5R and CYPOR for thyroid cancer. The aim was to assess the activity of CYB5R and CYPOR in thyroid tissues in benign and malignant thyroid neoplasms.
Methods 36 patients with thyroid neoplasms participated in the study. The control euthyroid goiter group included 10 patients; the thyrotoxic nodular goiter group included 14 patients; the papillary thyroid cancer T1-2N0-1M0 (PTC) group included 12 patients. The activity of CYB5R and CYPOR was assessed with lucigenin-enhanced chemiluminescence stimulated by NADH and NADPH, respectively.
Results The activity of CYB5R and CYPOR increased several times in thyrotoxicosis and approximately by an order of magnitude in some cases of PTC, but the activity change of CYPOR was more pronounced compared to CYB5R. For the PTC group, the subgroups with low and high activity of microsomal reductases were detected. Microsomal reductases in follicular adenoma was 2–4-fold less active compared to nontoxic goiter and the low-activity PTC group.
Conclusions Activity of microsomal reductases varies in thyroid pathology and can serve as a diagnostic and prognostic parameter in papillary thyroid cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is supported by the Ministry of Science and Higher Education of the Russian Federation, Project No 0400-2020-008.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of Inozemtsev City Clinical Hospital (Approval No. 12, 11.10.2019)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos